Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Refractory Ovarian and Primary Peritoneal Cancer
NCT00036751Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Response Rate (Confirmed, Complete, and Partial) up to 3 years. Started Apr 2002; status: completed.
02
Drugs
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00036751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036751.